small molecule

INCIVEK

TELAPREVIR

Loss of exclusivityMay 2028latest FDA-listed patent expiry
CompanyVERTEX PHARMACEUTICALS INC

Drug detail

Brand nameINCIVEK
Active ingredientTELAPREVIR
Strength375MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2011
Marketing statusDISCN

Listed patents

PatentExpiresType
8431615May 2028use U-1398

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INCIVEK patent cliff — loss of exclusivity May 2028 | CliffBio